Healthcare Equipment and Supplies
Company Overview of Ekso Bionics Holdings, Inc.
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company’s Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exo...
1414 Harbour Way South
Richmond, CA 94804
Founded in 2005
Key Executives for Ekso Bionics Holdings, Inc.
Chief Financial Officer
Total Annual Compensation: $242.7K
Chief Operating Officer
Total Annual Compensation: $301.1K
Chief Marketing Officer
Total Annual Compensation: $307.3K
Compensation as of Fiscal Year 2016.
Ekso Bionics Holdings, Inc. Key Developments
Ekso Bionics® to Expand Clinical Trial Sites for Comparative Multicenter WISE Study
Feb 12 18
Ekso Bionics Holdings, Inc. announced that it will be expanding the first company-sponsored randomized, controlled clinical trial, the WISE (Walking Improvement for SCI with Exoskeletons) study, to TIRR Memorial Herman and Barrow Neurological Institute. Led by Dylan Edwards, Ph.D., P.T., of the Burke Medical Research Institute, the U.S. based-study, which will now be conducted at ten centers, will evaluate improvement in independent gait speeds of patients with spinal cord injuries (SCI) who are receiving rehabilitation with the EksoGT™, the Company’s wearable exoskeleton, compared to standard of care. In addition to the two new participating WISE study sites, the following centers have been initiated: Burke Medical Research Institute, Courage Kenny Rehabilitation Institute, DMC Rehabilitation Institute of Michigan, Gaylord Hospital, Kennedy Krieger Institute, Kessler Foundation, Marianjoy Rehabilitation Hospital, part of Northwestern Medicine and Shirley Ryan AbilityLab. The multicenter WISE study incorporates three randomized clinical arms. Participants in Group 1 will undergo rehabilitation with a combination of the EksoGT™ and overground walking three times a week for 12 weeks. Group 2 will undergo rehabilitation consisting of standard gait training three times a week utilizing a combination of body-weight supported treadmill training and overground training for 12 weeks. Group 3 will be a passive control group; participants will continue with normal daily activities for 12 weeks with no therapy. All groups will be evaluated at baseline, 6 weeks, and 12 weeks. The primary endpoint of the WISE study seeks to demonstrate that a 12-week robotic gait training regimen can lead to a clinically meaningful improvement in independent walking speed. Secondary endpoints from the trial will examine economic factors such as number of physical therapists and staff required during training, the physical burden on physical therapists assisting and supervising during training, and the influence of factors that may modify the gait recovery.
Ekso Bionics Holdings, Inc. Announces Resignation of Russdon Angold as the President of the EksoWorks
Jan 26 18
Effective January 22, 2018, Russdon Angold resigned as the President of the EksoWorks business unit of Ekso Bionics Holdings, Inc. and from all other positions with the company in connection with a leadership transition in the Company.
Ekso Bionics Holdings, Inc. Provides Sales Guidance for the Fourth Quarter and Full Year Ended December 31, 2017
Jan 9 18
Ekso Bionics Holdings, Inc. provided sales guidance for the fourth quarter and full year ended December 31, 2017. For the quarter, the company expects to report revenue of over $2.5 million.
For the year, total revenue was approximately $7.4 million, compared to $7.7 million in 2016, excluding a one-time recognition of $6.5 million in 2016 of deferred revenue on previously shipped units.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|